Lupin signs exclusive licensing deal with Valorum for biosimilar Armlupeg in the U.S.

India, Dec. 4 -- Global pharmaceutical company Lupin Limited has entered into an exclusive licensing agreement with U.S.-based biosimilar specialist Valorum Biologics for the commercialization of its biosimilar Armlupeg™ (pegfilgrastim-unne) in the United States.

Under the agreement, Valorum will handle the commercialization and distribution of Armlupeg in the U.S., while Lupin will remain responsible for the manufacturing and supply of the product. Lupin will receive an upfront licensing fee along with royalty payments based on net sales.

Spiro Gavaris, President – U.S. Generics at Lupin, said the partnership will enhance access to affordable treatment options for chemotherapy patients and strengthen Lupin's presence in the U...